Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Peptide presented by HLA-A*01:01
- Molecular classification
- HLA class I/peptide complex, Receptor (HLA acts as a presenting molecule), Immune complex
01
Overview
HLA-A*01:01 is a highly polymorphic HLA class I molecule found on the surface of almost all nucleated cells. It binds short peptides (typically 8–11 amino acids) derived from intracellular proteins and displays them for recognition by cytotoxic CD8+ T cells. The specificity of immune responses, including T-cell receptor engagement and subsequent cytolysis or immunoregulation, depends on both the sequence of the presented peptide and the HLA allele[2][7][5]. The designation \"undisclosed peptide\" means the actual sequence and origin of the antigen are unspecified, precluding unique functional, drug, or disease associations for this entry.
- Other names
- Peptide/HLA-A*01:01 complexHLA-A*01:01/peptide complexHLA-A*01:01-restricted peptide
02
Mechanism of action
T cell activation via recognition of the peptide-HLA-A*01:01 complex\nInduction of cytotoxicity or immune modulation by antigen-specific T cells
03
Biological functions
Antigen presentationImmune response activationT cell-mediated cytotoxicity
04
Disease associations
Infection (viral, bacterial, etc.)Cancer (tumor antigens presented to T cells)Autoimmune diseaseOther immune-related diseases
05
Safety considerations
Potential for autoimmune reactions if presented peptides resemble self-antigensImmune escape due to tumor or pathogen mutations in peptide epitopesOff-target toxicity in T-cell therapies targeting peptide/HLA complexes
06
Interacting drugs
None specific; some immunotherapies (e.g., checkpoint inhibitors, cancer vaccines, peptide vaccines) target or depend on specific peptides in HLA context, but without knowing the particular peptide, no specific drugs can be listed.
07
Biomarkers
Presence of specific peptides presented by HLA-A*01:01 can be used as biomarkers in individualized immunotherapies, but the specific biomarker depends on the peptide. HLA-A*01:01 typing can be used for patient stratification
Beyond the preview
Go deeper on Peptide presented by HLA-A*01:01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Peptide presented by HLA-A*01:01.